Trail Ridge Investment Advisors’s Harmony Biosciences HRMY Stock Holding History

Trail Ridge Investment Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$244K	Buy	8,694 +385	+5%	+$12.6K	0.11%	94
2025 Q4	$311K	Sell	8,309 -535	-6%	-$17.6K	0.13%	89
2025 Q3	$244K	Buy	8,844 +300	+4%	+$10.3K	0.11%	99
2025 Q2	$301K	Sell	8,544 -1,266	-13%	-$40.7K	0.14%	86
2025 Q1	$326K	Buy	9,810 +766	+8%	+$27.5K	0.17%	82
2024 Q4	$311K	Sell	9,044 -8	-0.1%	-$275	0.15%	89
2024 Q3	$308K	Sell	9,052 -220	-2%	-$7.73K	0.15%	92
2024 Q2	$280K	Buy	9,272 +1,015	+12%	+$30.5K	0.14%	93
2024 Q1	$277K	Buy	+8,257	New	+$265K	0.16%	90

Other funds holding HRMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Trail Ridge Investment Advisors's HRMY Position: Q1 2026 in Review

Trail Ridge Investment Advisors increased its Harmony Biosciences (HRMY) stake by 4.6% in Q1 2026, buying an estimated $12.6K and bringing the position to 8,694 shares worth $244K. The position accounts for 0.11% of the portfolio, ranked #94.

Trail Ridge Investment Advisors first reported a position in HRMY in Q1 2024 and has held it in 9 quarters since. The position peaked at $326K in Q1 2025. 309 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

Trail Ridge Investment Advisors held 8,694 shares of Harmony Biosciences worth $244K as of Q1 2026.
Trail Ridge Investment Advisors bought 385 Harmony Biosciences shares in Q1 2026, an estimated $12.6K.
Harmony Biosciences made up 0.11% of Trail Ridge Investment Advisors's portfolio in Q1 2026, its #94 holding.
Trail Ridge Investment Advisors first reported a position in Harmony Biosciences in Q1 2024 and has held it in 9 quarters since.
Trail Ridge Investment Advisors's Harmony Biosciences position peaked at $326K in Q1 2025.
309 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Trail Ridge Investment Advisors's 13F filing for Q1 2026, filed 5 May 2026.